ARGX stock forecast, quote, news & analysis
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases... Show more
Why argenx SE (ARGX) Is Down -8% in the Last 30 Days
Key Takeaways
- ARGX stock declined -8% over the last 30 days amid broader biotech sector volatility and profit-taking following strong 2025 results.
- Over the past quarter, the stock fell -18%, reflecting a pullback from year-end highs despite robust Vyvgart sales growth.
- Positive clinical data for Vyvgart in ocular MG and seronegative gMG supported long-term outlook, but short-term market sentiment weighed on price.
- Full-year 2025 net product sales surged 90% to $4.2 billion, driving first-year operating profitability.
- Pipeline advancements, including AAN 2026 data presentations, highlight expansion potential in autoimmune diseases.
- Analyst upgrades and attractive valuation multiples signal confidence in future growth.
argenx SE (ARGX) Company Overview and Market Position
argenx SE is a commercial-stage biopharmaceutical company focused on developing antibody-based therapies for severe autoimmune diseases. Headquartered in Amsterdam, the Netherlands, argenx leverages its proprietary Simple Antibody platform, inspired by llama immunology, to create differentiated treatments. Its flagship product, Vyvgart (efgartigimod), targets the FcRn receptor to reduce harmful antibodies in conditions like generalized myasthenia gravis (gMG), chronic inflammatory demyelinating polyneuropathy (CIDP), and immune thrombocytopenia (ITP).
In the competitive biotech landscape, argenx holds a strong position in immunology, with Vyvgart establishing blockbuster status through rapid market penetration and label expansions. Strategic partnerships with companies like AbbVie and Genmab enhance its global reach. The company's fundamentals, including consistent revenue growth from Vyvgart and a deepening pipeline, underpin its resilience amid stock price fluctuations, as expanding indications address larger patient populations in underserved markets.
argenx SE (ARGX) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, ARGX stock declined approximately -8%, moving from around $750 in early March to a recent close near $691. The price action was volatile and trend-driven downward, with sharp drops in mid-March—such as a 6% single-day fall on March 20—interspersed with brief recoveries. Trading volume spiked during sell-offs, averaging over 370,000 shares daily, indicating heightened investor activity.
For the past quarter, the stock shed -18%, retreating from roughly $840 at year-end 2025 to current levels. This range-bound yet downward-biased movement reflected a steady pullback below the 50-day moving average of about $785, amid broader market trends in biotech. The 52-week range spans $510 to $935, positioning recent prices in the middle but off recent highs.
What Drove ARGX Stock Price in the Last 30 Days
The 30-day downturn was influenced by sector-wide biotech pressures and profit-taking after argenx's strong full-year 2025 earnings release in late February, which reported $4.2 billion in Vyvgart net sales—a 90% increase—and first operating profitability. While these fundamentals were positive, investors appeared to lock in gains as shares traded below short-term moving averages.
Mixed analyst adjustments contributed, with some price target trims amid valuation scrutiny, though upgrades like Deutsche Bank's to Buy highlighted intact commercial momentum. Positive Phase 3 data from the ADAPT OCULUS study for Vyvgart in ocular MG, announced in early March, provided support but failed to reverse the trend amid macroeconomic caution on growth stocks. Heightened volatility around AAN 2026 data previews further pressured sentiment, connecting to broader market trends favoring value over high-growth biotechs.
What Drove ARGX Stock Performance Over the Last Quarter
The quarterly decline stemmed from a sustained narrative of post-peak correction after Vyvgart-driven highs in late 2025, exacerbated by biotech sector headwinds like rising interest rate sensitivity and competition concerns. Despite Q4 sales hitting $1.3 billion, the stock pulled back as investors digested pipeline risks, including halted trials in thyroid eye disease.
Macro factors, such as inflation and regulatory scrutiny in immunology, amplified the move, while institutional behavior shifted toward diversified plays. However, cumulative positives like 19,000 patients on Vyvgart, Japan approvals for self-injection, and sBLA filings for seronegative gMG bolstered the base. Competitive positioning remained robust, with argenx capturing market share in MG and CIDP, though broader industry developments tempered enthusiasm.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots from hundreds available, which analyze thousands of tickers across various strategies, timeframes, and performance metrics. These curated bots, selected based on recent success rates, win ratios, and relevance to current market trends, help traders identify opportunities in stocks like ARGX through pattern recognition, momentum signals, and predictive modeling. Whether focusing on short-term scalping or long-term trends, the section highlights bots with proven edges in volatile biotech sectors. Explore the page to see real-time rankings and integrate these tools into your stock analysis workflow.
ARGX Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor upcoming PDUFA dates, including May 2026 for Vyvgart in seronegative gMG, and Phase 3 readouts at AAN 2026 for ocular MG, CIDP expansions, myositis, and MMN. Pipeline progress with empasiprubart and new Phase 1 entrants like ARGX-118 will signal diversification beyond FcRn inhibitors.
Industry trends in autoimmune therapies, such as competition from subcutaneous rivals, and macroeconomic shifts like interest rates impacting biotech valuations, remain key. Strategic developments, including international launches and partnerships, alongside quarterly Vyvgart sales updates, could sway sentiment. Risks include trial setbacks or regulatory delays, while catalysts like label broadenings offer upside potential.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
Momentum Indicator for ARGX turns positive, indicating new upward trend
ARGX saw its Momentum Indicator move above the 0 level on March 30, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned positive. In of the 89 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ARGX just turned positive on March 26, 2026. Looking at past instances where ARGX's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .
ARGX moved above its 50-day moving average on April 08, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ARGX crossed bullishly above the 50-day moving average on April 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ARGX advanced for three days, in of 311 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARGX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ARGX broke above its upper Bollinger Band on March 31, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ARGX entered a downward trend on March 31, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ARGX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.032) is normal, around the industry mean (26.452). P/E Ratio (42.328) is within average values for comparable stocks, (46.078). Projected Growth (PEG Ratio) (1.314) is also within normal values, averaging (1.789). Dividend Yield (0.000) settles around the average of (0.033) among similar stocks. P/S Ratio (13.175) is also within normal values, averaging (320.063).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of antibody-based medicines
Industry Biotechnology